Compare Stocks: RANI, EDIT, CCCC, and ARCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.23 -3.5%	$9.29	$5.50 ▼ $24.17	$403.85M	2.48	603,023 shs	609,880 shs
CCCC C4 Therapeutics	$3.33 -3.3%	$3.86	$1.69 ▼ $5.17	$409.08M	2.94	2.66 million shs	545,958 shs
EDIT Editas Medicine	$2.64 -4.9%	$3.02	$1.66 ▼ $4.54	$404.68M	2.09	2.10 million shs	1.18 million shs
RANI Rani Therapeutics	$0.83 -1.5%	$0.80	$0.45 ▼ $3.87	$115.28M	0.69	972,620 shs	127,945 shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-5.69%	-11.95%	+109.08%	+111.93%	-17.84%
CCCC C4 Therapeutics	-3.10%	-9.23%	-4.97%	-11.11%	+28.36%
EDIT Editas Medicine	-8.58%	-10.06%	-1.42%	+13.52%	+0.36%
RANI Rani Therapeutics	-3.72%	-2.10%	+8.12%	+4.74%	+68.20%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$14.23 -3.5%	$9.29	$5.50 ▼ $24.17	$403.85M	2.48	603,023 shs	609,880 shs
CCCC C4 Therapeutics	$3.33 -3.3%	$3.86	$1.69 ▼ $5.17	$409.08M	2.94	2.66 million shs	545,958 shs
EDIT Editas Medicine	$2.64 -4.9%	$3.02	$1.66 ▼ $4.54	$404.68M	2.09	2.10 million shs	1.18 million shs
RANI Rani Therapeutics	$0.83 -1.5%	$0.80	$0.45 ▼ $3.87	$115.28M	0.69	972,620 shs	127,945 shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-5.69%	-11.95%	+109.08%	+111.93%	-17.84%
CCCC C4 Therapeutics	-3.10%	-9.23%	-4.97%	-11.11%	+28.36%
EDIT Editas Medicine	-8.58%	-10.06%	-1.42%	+13.52%	+0.36%
RANI Rani Therapeutics	-3.72%	-2.10%	+8.12%	+4.74%	+68.20%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	2.60	Moderate Buy	$23.00	61.69% Upside
CCCC C4 Therapeutics	2.60	Moderate Buy	$7.67	130.58% Upside
EDIT Editas Medicine	2.60	Moderate Buy	$6.00	127.70% Upside
RANI Rani Therapeutics	2.83	Moderate Buy	$8.75	958.04% Upside

Current Analyst Ratings Breakdown

Latest RANI, EDIT, CCCC, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	ARCT Arcturus Therapeutics	Roth Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$41.00
8/26/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/21/2026	RANI Rani Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	EDIT Editas Medicine	LADENBURG THALM/SH SH Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$6.00
8/18/2026	RANI Rani Therapeutics	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy
8/11/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/17/2026	ARCT Arcturus Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CCCC C4 Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	EDIT Editas Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
6/24/2026	RANI Rani Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$82.03M	4.93	N/A	N/A	$7.53 per share	1.89
CCCC C4 Therapeutics	$35.95M	11.38	N/A	N/A	$2.65 per share	1.25
EDIT Editas Medicine	$40.52M	9.99	N/A	N/A	$0.28 per share	9.41
RANI Rani Therapeutics	$1.63M	70.73	N/A	N/A	$0.34 per share	2.43

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$65.78M	-$3.31	N/A	N/A	N/A	-317.62%	-46.54%	-36.46%	11/9/2026 (Estimated)
CCCC C4 Therapeutics	-$104.99M	-$1.00	N/A	N/A	N/A	-289.44%	-45.45%	-30.90%	11/5/2026 (Estimated)
EDIT Editas Medicine	-$160.06M	-$0.75	N/A	N/A	N/A	-157.32%	-196.63%	-38.17%	11/9/2026 (Estimated)
RANI Rani Therapeutics	-$29.67M	-$0.27	N/A	N/A	N/A	N/A	-104.60%	-65.17%	11/5/2026 (Estimated)

Latest RANI, EDIT, CCCC, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	RANI Rani Therapeutics	-$0.05	-$0.04	+$0.01	-$0.04	$0.93 million	$1.71 million
8/11/2026	Q2 2026	CCCC C4 Therapeutics	-$0.2264	-$0.18	+$0.0464	-$0.18	$4.00 million	$6.64 million
8/7/2026	Q2 2026	ARCT Arcturus Therapeutics	-$0.9964	-$0.84	+$0.1564	-$0.84	$3.11 million	$2.96 million
8/5/2026	Q2 2026	EDIT Editas Medicine	-$0.2705	-$0.15	+$0.1205	-$0.15	$2.85 million	$11.89 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	N/A	N/A	N/A	N/A	N/A
CCCC C4 Therapeutics	N/A	N/A	N/A	N/A	N/A
EDIT Editas Medicine	N/A	N/A	N/A	N/A	N/A
RANI Rani Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	5.88	5.88
CCCC C4 Therapeutics	N/A	5.45	5.45
EDIT Editas Medicine	N/A	3.19	3.19
RANI Rani Therapeutics	N/A	5.31	5.31

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CCCC C4 Therapeutics	78.81%
EDIT Editas Medicine	71.90%
RANI Rani Therapeutics	30.19%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	17.80%
CCCC C4 Therapeutics	5.60%
EDIT Editas Medicine	3.10%
RANI Rani Therapeutics	26.73%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	28.42 million	23.36 million	Optionable
CCCC C4 Therapeutics	150	123.03 million	116.14 million	Optionable
EDIT Editas Medicine	230	153.58 million	148.82 million	Optionable
RANI Rani Therapeutics	110	139.40 million	102.14 million	Optionable

RANI, EDIT, CCCC, and ARCT Headlines

Recent News About These Companies

Rani Therapeutics to Participate in Upcoming September Conferences

September 8 at 8:00 AM | globenewswire.com

Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

August 29, 2026 | marketbeat.com

Chardan Capital Upgrades Rani Therapeutics (NASDAQ:RANI) to Strong-Buy

August 28, 2026 | marketbeat.com

AWM Investment Company Inc. Purchases Shares of 7,500,000 Rani Therapeutics Holdings, Inc. $RANI

August 26, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Rani Therapeutics Holdings (RANI) and Sanofi (OtherSNYNF)

August 25, 2026 | theglobeandmail.com

HC Wainwright Issues Pessimistic Forecast for RANI Earnings

August 25, 2026 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Rani Therapeutics (NASDAQ:RANI)

August 21, 2026 | marketbeat.com

Canaccord Genuity Sticks to Its Buy Rating for Kymera Therapeutics (KYMR)

August 20, 2026 | theglobeandmail.com

Chardan Capital Initiates Coverage on Rani Therapeutics (NASDAQ:RANI)

August 18, 2026 | marketbeat.com

Rani Therapeutics Expands Oral Biologics Push With Obesity, Immunology Pipeline

August 16, 2026 | marketbeat.com

Rani Therapeutics (NASDAQ:RANI) Announces Earnings Results, Beats Expectations By $0.01 EPS

August 13, 2026 | marketbeat.com

Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update

August 13, 2026 | globenewswire.com

Rani Therapeutics to Participate in the Canaccord Genuity 46th Annual Growth Conference

August 10, 2026 | markets.businessinsider.com

Rani Therapeutics Appoints Michelle Gilson to Board of Directors and Names Her Audit Committee Chair

August 4, 2026 | quiverquant.comQ

Rani Therapeutics (NASDAQ:RANI) CEO Talat Imran Sells 8,014 Shares of Stock

July 29, 2026 | insidertrades.com

Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

July 20, 2026 | globenewswire.com

Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing

July 15, 2026 | globenewswire.com

Rani Therapeutics Holdings (RANI) Declines 7.95%, Testing Key Support at $0.60 - Strangle Setup

July 14, 2026 | donanimhaber.comD

Rani Therapeutics Holdings Inc - Ordinary Shares Class A

July 13, 2026 | money.usnews.com

Rani Therapeutics enters R&D collaboration with PegBio to expand obesity pipeline across multiple novel candidates

July 13, 2026 | pharmabiz.comP

Why Did Rani Therapeutics (NASDAQ:RANI) Announce New Collaboration?

July 10, 2026 | kalkinemedia.comK

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

RANI, EDIT, CCCC, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$14.22 -0.52 (-3.49%)

As of 01:14 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

C4 Therapeutics NASDAQ:CCCC

$3.32 -0.12 (-3.34%)

As of 01:15 PM Eastern

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting IKZF1 and IKZF3 for multiple myeloma and non-Hodgkin lymphomas, including peripheral T-cell lymphoma and mantle cell lymphoma, currently under Phase 1/2 clinical trials. The company is also developing CFT1946, an orally bioavailable BiDAC degrader targeting V600X mutant BRAF to treat melanoma, non-small cell lung cancer (NSCLC), colorectal cancer, and other solid malignancies, currently under Phase 1/2 clinical trials; and CFT8919, an orally bioavailable, allosteric, and mutant-selective BiDAC degrader of epidermal growth factor receptor, or EGFR, with an L858R mutation in NSCLC. It has strategic collaborations with F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; Biogen MA, Inc.; Betta Pharmaceuticals, Co., Ltd.; and Merck Sharp & Dohme, LLC, as well as Calico Life Sciences LLC. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Editas Medicine NASDAQ:EDIT

$2.64 -0.14 (-4.87%)

As of 01:15 PM Eastern

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Rani Therapeutics NASDAQ:RANI

$0.83 -0.01 (-1.55%)

As of 01:14 PM Eastern

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RANI, EDIT, CCCC, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RANI, EDIT, CCCC, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RANI, EDIT, CCCC, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RANI, EDIT, CCCC, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

C4 Therapeutics NASDAQ:CCCC

Editas Medicine NASDAQ:EDIT

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest RANI, EDIT, CCCC, and ARCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest RANI, EDIT, CCCC, and ARCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

RANI, EDIT, CCCC, and ARCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

RANI, EDIT, CCCC, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

C4 Therapeutics NASDAQ:CCCC

Editas Medicine NASDAQ:EDIT

Rani Therapeutics NASDAQ:RANI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools